Upsher-Smith Laboratories on Wednesday announced the launch of testosterone gel (1%), the generic of Vogelxo (testosterone) gel 1%, for topical use. Newly approved by the Food and Drug Administration, it is the first and only available generic testosterone replacement therapy available in three configurations, the company stated.
Almost 70% of adults with Type 1 diabetes never use their blood glucose self-monitoring devices or insulin pumps to download historical data about their blood sugar levels and insulin doses — information that likely would help them manage their disease better.
Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism, providing a new way for diabetics to administer their insulin.
The American Diabetes Association will lower its target recommendation for blood glucose levels for children with Type 1 diabetes, according to a statement released at the association's 74th Scientific Sessions.
New research presented at the June 2014 American Diabetes Association Scientific Sessions suggests that canola oil helps control blood glucose in people with Type 2 diabetes when it's incorporated into a low-glycemic index diet.
Auxilium Pharmaceuticals, a specialty biopharmaceutical company, on Wednesday announced that it has partnered with Prasco to debut the authorized generic form of Testim gel, which is used to treat adult males with low or no testosterone.
A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.
More than 29 million people in the United States have diabetes, up from the previous estimate of 26 million in 2010, according to a report released Tuesday by the Centers for Disease Control and Prevention.
Upsher-Smith Laboratories on Wednesday announced that it has received final approval from the Food and Drug Administration for its new drug application for Vogelxo (testosterone) gel for topical use CIII.
Trimel Pharmaceuticals on Wednesday announced that the Food and Drug Administration has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
New research published in Diabetologia, the journal of the European Association for the Study of Diabetes, found that brief bursts of intense exercise before meals — termed exercise "snacking" by the study authors — helps control blood sugar in people with insulin resistance more effectively than one daily 30-minute session of moderate exercise.
i-Health has been carving out new niches with its feminine pain reliever brand Estroven, which as a brand family generated more than $37.2 million in sales across total U.S. multi-outlets for the 52 weeks ended Dec. 29, 2013, according to IRI.
Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.
Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.
MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.
In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease, adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.
Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.
AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.
The Food and Drug Administration recently approved two "robotic pills," or pills that place an image camera or ingestible sensors into the gastrointestinal tract, according to a report published earlier this week by the Wall Street Journal.